STOCK TITAN
  1. Home
  2. Sec-filings
  3. KYMR
  4. [Form 4] Kymera Therapeutics, Inc. Insider Trading Activity

Kymera (KYMR) CMO Form 4: options at $1.31 and $2.08

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Kymera Therapeutics (KYMR) Form 4: The Chief Medical Officer reported transactions on 10/15/2025 under a Rule 10b5-1 trading plan dated June 2, 2025. He exercised 28,999 stock options at $1.31 and 22,210 options at $2.08, adding shares via option exercises.

He then sold 29,264 shares at a weighted average price of $60.37, 8,963 at $61.4929, 14,896 at $62.7233, and 6,453 at $63.0868. Following these transactions, he beneficially owned 109,992 shares directly.

Positive

  • None.

Negative

  • None.
Insider Gollob Jared
Role Chief Medical Officer
Sold 59,576 shs ($3.66M)
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) 28,999 $0.00 --
Exercise Stock Option (Right to Buy) 22,210 $0.00 --
Exercise Common Stock 28,999 $1.31 $38K
Exercise Common Stock 22,210 $2.08 $46K
Sale Common Stock 29,264 $60.37 $1.77M
Sale Common Stock 8,963 $61.4929 $551K
Sale Common Stock 14,896 $62.7233 $934K
Sale Common Stock 6,453 $63.0868 $407K
Holdings After Transaction: Stock Option (Right to Buy) — 0 shares (Direct); Common Stock — 147,358 shares (Direct)
Footnotes (1)
  1. These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 2, 2025 adopted by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.01 to $62.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.01 to $63.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.02 to $63.28, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The shares underlying this stock option are fully vested and exercisable.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Gollob Jared
(Last) (First) (Middle)
C/O KYMERA THERAPEUTICS, INC.
500 NORTH BEACON STREET, 4TH FLOOR
(Street)
WATERTOWN MA 02472
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Medical Officer
3. Date of Earliest Transaction (Month/Day/Year)
10/15/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/15/2025 M(1) 28,999 A $1.31 147,358 D
Common Stock 10/15/2025 M(1) 22,210 A $2.08 169,568 D
Common Stock 10/15/2025 S(1) 29,264 D $60.37(2) 140,304 D
Common Stock 10/15/2025 S(1) 8,963 D $61.4929(3) 131,341 D
Common Stock 10/15/2025 S(1) 14,896 D $62.7233(4) 116,445 D
Common Stock 10/15/2025 S(1) 6,453 D $63.0868(5) 109,992 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $1.31 10/15/2025 M(1) 28,999 (6) 10/31/2028 Common Stock 28,999 $0 0 D
Stock Option (Right to Buy) $2.08 10/15/2025 M(1) 22,210 (6) 05/22/2029 Common Stock 22,210 $0 0 D
Explanation of Responses:
1. These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 2, 2025 adopted by the reporting person.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.01 to $62.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.01 to $63.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.02 to $63.28, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
6. The shares underlying this stock option are fully vested and exercisable.
/s/ Bruce Jacobs, as Attorney-in-Fact 10/15/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did KYMR's CMO report on the Form 4?

He exercised stock options and sold common shares on 10/15/2025 under a Rule 10b5-1 plan dated June 2, 2025.

How many Kymera (KYMR) options were exercised and at what prices?

He exercised 28,999 options at $1.31 and 22,210 options at $2.08.

How many KYMR shares were sold and at what prices?

Sales included 29,264 at $60.37, 8,963 at $61.4929, 14,896 at $62.7233, and 6,453 at $63.0868 (weighted averages).

What is the officer’s role at Kymera Therapeutics (KYMR)?

He is the Chief Medical Officer.

How many KYMR shares did the officer hold after the transactions?

He beneficially owned 109,992 shares directly after the reported transactions.

Were these trades part of a prearranged plan?

Yes. The filing states they were effected pursuant to a Rule 10b5-1 plan dated June 2, 2025.